Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment.
This study investigated the effects of antidepressant treatment on platelet activation in depressed patients with ischemic heart disease (IHD). Plasma levels of platelet alpha-granule release products beta-thromboglobulin (BTG) and platelet factor 4 (PF4) were measured in 17 depressed patients with IHD who were treated in a 6-week, double-blind trial with either paroxetine (10 patients) or nortriptyline (7 patients). Baseline measurements of BTG and PF4 were significantly elevated in both drug treatment groups before the initiation of antidepressant therapy compared with those of healthy control subjects. In the paroxetine group, mean PF4 and BTG levels significantly decreased from these elevated baseline values within 1 week of treatment and remained low at 3- and 6-week measurements. In contrast, the nortriptyline group did not exhibit a significant decrease in PF4 or BTG plasma levels after 1, 3, or 6 weeks of treatment. Therefore, platelet activation in depressed patients with IHD seems to be inhibited by the selective serotonin reuptake inhibitor paroxetine. The effect of paroxetine on PF4 and BTG plasma levels suggests that it may reduce platelet aggregation in vivo and may positively impact IHD-related mortality in this population.
Pollock
B G
BG
Department of Psychiatry, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, Pennsylvania, USA. pollockbg@msx.upmc.edu
Laghrissi-Thode
F
F
Wagner
W R
WR
D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage* / Q000009:adverse effects; D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage* / Q000009:adverse effects; D003327:Coronary Disease / Q000097:blood* / Q000523:psychology; D003866:Depressive Disorder / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D006801:Humans; D009661:Nortriptyline / Q000008:administration & dosage* / Q000009:adverse effects; D017374:Paroxetine / Q000008:administration & dosage* / Q000009:adverse effects; D015539:Platelet Activation / Q000187:drug effects*; D010974:Platelet Aggregation / Q000187:drug effects; D010978:Platelet Factor 4 / Q000378:metabolism; D001620:beta-Thromboglobulin / Q000378:metabolism
D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D001620:beta-Thromboglobulin; D010978:Platelet Factor 4; D017374:Paroxetine; D009661:Nortriptyline